Epilepsy Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036
The 7 major epilepsy markets reached a value of USD 2.05 Billion in 2025. Looking forward, IMARC Group expects the 7MM to reach USD 2.71 Billion by 2036, exhibiting a growth rate (CAGR) of 2.58% during 2026-2036.
The epilepsy market has been comprehensively analyzed in IMARC's new report titled "Epilepsy Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook". Epilepsy is a neurological condition distinguished by recurrent seizures, which are sudden and uncontrolled bursts of electrical activity in the brain. These seizures are brief periods of uncontrollable movement involving a portion of the body (partial) or the entire body (generalized) and are occasionally followed by loss of awareness and control of bowel or bladder function. Symptoms of epilepsy can vary widely, but common ones include convulsions, loss of consciousness, and muscle spasms. Epilepsy is often diagnosed through a medical history review, physical examination, imaging tests, and diagnostic testing, such as an electroencephalogram (EEG). Diagnosis of epilepsy may also entail ruling out other illnesses that may cause seizures. Treatment for epilepsy typically consists of a combination of medications and lifestyle changes.
The rising prevalence of several associated risk factors, including neurological disorders, birth-related injuries, infections, substance abuse, road accidents, etc., is primarily driving the global epilepsy market. In addition to this, the expanding geriatric population, who are more prone to developing age-related conditions, such as Alzheimer's disease or Parkinson's disease, that can increase the risk of epilepsy, is also augmenting the market growth. Moreover, the widespread adoption of anti-epileptic drugs (AEDs) for treating epilepsy, which stabilize the electrical activity in the brain and prevent seizures, is also creating a positive outlook for the market. Apart from this, the increasing utilization of vagus nerve stimulation (VNS) devices to help reduce the frequency of seizures is further acting as a significant growth-inducing factor. The device can be programmed to deliver stimulation at specific times and intensities, and can be adjusted as needed. Additionally, the ongoing development of extended-release (ER) drug formulations that allow longer dosing intervals while minimizing the fluctuations in serum drug levels, thus improving efficacy as compared to immediate-release (IR) drugs, is also propelling the global market. Besides this, the implementation of numerous government initiatives to raise awareness about the ailment, promote research, and offer active assistance by expediting the development of better treatment options is further augmenting the market growth. Additionally, several key players are making significant investments in R&D activities aimed at introducing novel medications that are less expensive, more effective, and have fewer adverse effects. This, in turn, is expected to drive the global epilepsy market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the epilepsy market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for epilepsy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the epilepsy market in any manner.
Time Period of the Study
This report also provides a detailed analysis of the current epilepsy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Market Insights
The epilepsy market has been comprehensively analyzed in IMARC's new report titled "Epilepsy Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook". Epilepsy is a neurological condition distinguished by recurrent seizures, which are sudden and uncontrolled bursts of electrical activity in the brain. These seizures are brief periods of uncontrollable movement involving a portion of the body (partial) or the entire body (generalized) and are occasionally followed by loss of awareness and control of bowel or bladder function. Symptoms of epilepsy can vary widely, but common ones include convulsions, loss of consciousness, and muscle spasms. Epilepsy is often diagnosed through a medical history review, physical examination, imaging tests, and diagnostic testing, such as an electroencephalogram (EEG). Diagnosis of epilepsy may also entail ruling out other illnesses that may cause seizures. Treatment for epilepsy typically consists of a combination of medications and lifestyle changes.
The rising prevalence of several associated risk factors, including neurological disorders, birth-related injuries, infections, substance abuse, road accidents, etc., is primarily driving the global epilepsy market. In addition to this, the expanding geriatric population, who are more prone to developing age-related conditions, such as Alzheimer's disease or Parkinson's disease, that can increase the risk of epilepsy, is also augmenting the market growth. Moreover, the widespread adoption of anti-epileptic drugs (AEDs) for treating epilepsy, which stabilize the electrical activity in the brain and prevent seizures, is also creating a positive outlook for the market. Apart from this, the increasing utilization of vagus nerve stimulation (VNS) devices to help reduce the frequency of seizures is further acting as a significant growth-inducing factor. The device can be programmed to deliver stimulation at specific times and intensities, and can be adjusted as needed. Additionally, the ongoing development of extended-release (ER) drug formulations that allow longer dosing intervals while minimizing the fluctuations in serum drug levels, thus improving efficacy as compared to immediate-release (IR) drugs, is also propelling the global market. Besides this, the implementation of numerous government initiatives to raise awareness about the ailment, promote research, and offer active assistance by expediting the development of better treatment options is further augmenting the market growth. Additionally, several key players are making significant investments in R&D activities aimed at introducing novel medications that are less expensive, more effective, and have fewer adverse effects. This, in turn, is expected to drive the global epilepsy market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the epilepsy market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for epilepsy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the epilepsy market in any manner.
Time Period of the Study
- Base Year: 2025
- Historical Period: 2020-2025
- Market Forecast: 2026-2036
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the epilepsy market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the epilepsy market
- Reimbursement scenario in the market
- In-market and pipeline drugs
This report also provides a detailed analysis of the current epilepsy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Market Insights
- How has the epilepsy market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2025 and how are they expected to perform till 2036?
- What was the country-wise size of the epilepsy market across the seven major markets in 2025 and what will it look like in 2036?
- What is the growth rate of the epilepsy market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 EPILEPSY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2020-2025) and Forecast (2026-2036)
4.4 Market Overview (2020-2025) and Forecast (2026-2036)
4.5 Competitive Intelligence
5 EPILEPSY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 EPILEPSY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2020-2025)
7.2.2 Epidemiology Forecast (2026-2036)
7.2.3 Epidemiology by Age (2020-2036)
7.2.4 Epidemiology by Gender (2020-2036)
7.2.5 Epidemiology by Type (2020-2036)
7.2.6 Diagnosed Cases (2020-2036)
7.2.7 Patient Pool/Treated Cases (2020-2036)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2020-2025)
7.3.2 Epidemiology Forecast (2026-2036)
7.3.3 Epidemiology by Age (2020-2036)
7.3.4 Epidemiology by Gender (2020-2036)
7.3.5 Epidemiology by Type (2020-2036)
7.3.6 Diagnosed Cases (2020-2036)
7.3.7 Patient Pool/Treated Cases (2020-2036)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2020-2025)
7.4.2 Epidemiology Forecast (2026-2036)
7.4.3 Epidemiology by Age (2020-2036)
7.4.4 Epidemiology by Gender (2020-2036)
7.4.5 Epidemiology by Type (2020-2036)
7.4.6 Diagnosed Cases (2020-2036)
7.4.7 Patient Pool/Treated Cases (2020-2036)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2020-2025)
7.5.2 Epidemiology Forecast (2026-2036)
7.5.3 Epidemiology by Age (2020-2036)
7.5.4 Epidemiology by Gender (2020-2036)
7.5.5 Epidemiology by Type (2020-2036)
7.5.6 Diagnosed Cases (2020-2036)
7.5.7 Patient Pool/Treated Cases (2020-2036)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2020-2025)
7.6.2 Epidemiology Forecast (2026-2036)
7.6.3 Epidemiology by Age (2020-2036)
7.6.4 Epidemiology by Gender (2020-2036)
7.6.5 Epidemiology by Type (2020-2036)
7.6.6 Diagnosed Cases (2020-2036)
7.6.7 Patient Pool/Treated Cases (2020-2036)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2020-2025)
7.7.2 Epidemiology Forecast (2026-2036)
7.7.3 Epidemiology by Age (2020-2036)
7.7.4 Epidemiology by Gender (2020-2036)
7.7.5 Epidemiology by Type (2020-2036)
7.7.6 Diagnosed Cases (2020-2036)
7.7.7 Patient Pool/Treated Cases (2020-2036)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2020-2025)
7.8.2 Epidemiology Forecast (2026-2036)
7.8.3 Epidemiology by Age (2020-2036)
7.8.4 Epidemiology by Gender (2020-2036)
7.8.5 Epidemiology by Type (2020-2036)
7.8.6 Diagnosed Cases (2020-2036)
7.8.7 Patient Pool/Treated Cases (2020-2036)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2020-2025)
7.9.2 Epidemiology Forecast (2026-2036)
7.9.3 Epidemiology by Age (2020-2036)
7.9.4 Epidemiology by Gender (2020-2036)
7.9.5 Epidemiology by Type (2020-2036)
7.9.6 Diagnosed Cases (2020-2036)
7.9.7 Patient Pool/Treated Cases (2020-2036)
8 EPILEPSY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 EPILEPSY - UNMET NEEDS
10 EPILEPSY - KEY ENDPOINTS OF TREATMENT
11 EPILEPSY - MARKETED PRODUCTS
11.1 List of Epilepsy Marketed Drugs Across the Top 7 Markets
11.1.1 Lamictal (Lamotrigine) – GlaxoSmithKline
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Keppra (Levetiracetam) - GlaxoSmithKline/Otsuka Pharmaceuticals/UCB
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Topamax (Topiramate) – Janssen
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Zonegran (Zonisamide) – Eisai Co Ltd
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Briviact (Brivaracetam) - UCB Pharma
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
12 EPILEPSY - PIPELINE DRUGS
12.1 List of Epilepsy Pipeline Drugs Across the Top 7 Markets
12.1.1 SKL24741 - SK biopharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Ganaxolone - Marinus Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 SPN817 - Supernus Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Vormatrigine - Praxis Precision Medicines
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 BHV-7000 - Biohaven Pharmaceuticals
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 EPILEPSY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Epilepsy - Market Size
15.2.1.1 Market Size (2020-2025)
15.2.1.2 Market Forecast (2026-2036)
15.2.2 Epilepsy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2020-2025)
15.2.2.2 Market Forecast by Therapies (2026-2036)
15.3 Market Scenario - United States
15.3.1 Epilepsy - Market Size
15.3.1.1 Market Size (2020-2025)
15.3.1.2 Market Forecast (2026-2036)
15.3.2 Epilepsy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2020-2025)
15.3.2.2 Market Forecast by Therapies (2026-2036)
15.3.3 Epilepsy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Epilepsy - Market Size
15.4.1.1 Market Size (2020-2025)
15.4.1.2 Market Forecast (2026-2036)
15.4.2 Epilepsy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2020-2025)
15.4.2.2 Market Forecast by Therapies (2026-2036)
15.4.3 Epilepsy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Epilepsy - Market Size
15.5.1.1 Market Size (2020-2025)
15.5.1.2 Market Forecast (2026-2036)
15.5.2 Epilepsy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2020-2025)
15.5.2.2 Market Forecast by Therapies (2026-2036)
15.5.3 Epilepsy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Epilepsy - Market Size
15.6.1.1 Market Size (2020-2025)
15.6.1.2 Market Forecast (2026-2036)
15.6.2 Epilepsy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2020-2025)
15.6.2.2 Market Forecast by Therapies (2026-2036)
15.6.3 Epilepsy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Epilepsy - Market Size
15.7.1.1 Market Size (2020-2025)
15.7.1.2 Market Forecast (2026-2036)
15.7.2 Epilepsy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2020-2025)
15.7.2.2 Market Forecast by Therapies (2026-2036)
15.7.3 Epilepsy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Epilepsy - Market Size
15.8.1.1 Market Size (2020-2025)
15.8.1.2 Market Forecast (2026-2036)
15.8.2 Epilepsy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2020-2025)
15.8.2.2 Market Forecast by Therapies (2026-2036)
15.8.3 Epilepsy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Epilepsy - Market Size
15.9.1.1 Market Size (2020-2025)
15.9.1.2 Market Forecast (2026-2036)
15.9.2 Epilepsy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2020-2025)
15.9.2.2 Market Forecast by Therapies (2026-2036)
15.9.3 Epilepsy - Access and Reimbursement Overview
16 EPILEPSY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 EPILEPSY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 EPILEPSY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 EPILEPSY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2020-2025) and Forecast (2026-2036)
4.4 Market Overview (2020-2025) and Forecast (2026-2036)
4.5 Competitive Intelligence
5 EPILEPSY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 EPILEPSY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2020-2025)
7.2.2 Epidemiology Forecast (2026-2036)
7.2.3 Epidemiology by Age (2020-2036)
7.2.4 Epidemiology by Gender (2020-2036)
7.2.5 Epidemiology by Type (2020-2036)
7.2.6 Diagnosed Cases (2020-2036)
7.2.7 Patient Pool/Treated Cases (2020-2036)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2020-2025)
7.3.2 Epidemiology Forecast (2026-2036)
7.3.3 Epidemiology by Age (2020-2036)
7.3.4 Epidemiology by Gender (2020-2036)
7.3.5 Epidemiology by Type (2020-2036)
7.3.6 Diagnosed Cases (2020-2036)
7.3.7 Patient Pool/Treated Cases (2020-2036)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2020-2025)
7.4.2 Epidemiology Forecast (2026-2036)
7.4.3 Epidemiology by Age (2020-2036)
7.4.4 Epidemiology by Gender (2020-2036)
7.4.5 Epidemiology by Type (2020-2036)
7.4.6 Diagnosed Cases (2020-2036)
7.4.7 Patient Pool/Treated Cases (2020-2036)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2020-2025)
7.5.2 Epidemiology Forecast (2026-2036)
7.5.3 Epidemiology by Age (2020-2036)
7.5.4 Epidemiology by Gender (2020-2036)
7.5.5 Epidemiology by Type (2020-2036)
7.5.6 Diagnosed Cases (2020-2036)
7.5.7 Patient Pool/Treated Cases (2020-2036)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2020-2025)
7.6.2 Epidemiology Forecast (2026-2036)
7.6.3 Epidemiology by Age (2020-2036)
7.6.4 Epidemiology by Gender (2020-2036)
7.6.5 Epidemiology by Type (2020-2036)
7.6.6 Diagnosed Cases (2020-2036)
7.6.7 Patient Pool/Treated Cases (2020-2036)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2020-2025)
7.7.2 Epidemiology Forecast (2026-2036)
7.7.3 Epidemiology by Age (2020-2036)
7.7.4 Epidemiology by Gender (2020-2036)
7.7.5 Epidemiology by Type (2020-2036)
7.7.6 Diagnosed Cases (2020-2036)
7.7.7 Patient Pool/Treated Cases (2020-2036)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2020-2025)
7.8.2 Epidemiology Forecast (2026-2036)
7.8.3 Epidemiology by Age (2020-2036)
7.8.4 Epidemiology by Gender (2020-2036)
7.8.5 Epidemiology by Type (2020-2036)
7.8.6 Diagnosed Cases (2020-2036)
7.8.7 Patient Pool/Treated Cases (2020-2036)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2020-2025)
7.9.2 Epidemiology Forecast (2026-2036)
7.9.3 Epidemiology by Age (2020-2036)
7.9.4 Epidemiology by Gender (2020-2036)
7.9.5 Epidemiology by Type (2020-2036)
7.9.6 Diagnosed Cases (2020-2036)
7.9.7 Patient Pool/Treated Cases (2020-2036)
8 EPILEPSY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 EPILEPSY - UNMET NEEDS
10 EPILEPSY - KEY ENDPOINTS OF TREATMENT
11 EPILEPSY - MARKETED PRODUCTS
11.1 List of Epilepsy Marketed Drugs Across the Top 7 Markets
11.1.1 Lamictal (Lamotrigine) – GlaxoSmithKline
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Keppra (Levetiracetam) - GlaxoSmithKline/Otsuka Pharmaceuticals/UCB
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Topamax (Topiramate) – Janssen
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Zonegran (Zonisamide) – Eisai Co Ltd
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Briviact (Brivaracetam) - UCB Pharma
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
12 EPILEPSY - PIPELINE DRUGS
12.1 List of Epilepsy Pipeline Drugs Across the Top 7 Markets
12.1.1 SKL24741 - SK biopharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Ganaxolone - Marinus Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 SPN817 - Supernus Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Vormatrigine - Praxis Precision Medicines
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 BHV-7000 - Biohaven Pharmaceuticals
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 EPILEPSY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Epilepsy - Market Size
15.2.1.1 Market Size (2020-2025)
15.2.1.2 Market Forecast (2026-2036)
15.2.2 Epilepsy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2020-2025)
15.2.2.2 Market Forecast by Therapies (2026-2036)
15.3 Market Scenario - United States
15.3.1 Epilepsy - Market Size
15.3.1.1 Market Size (2020-2025)
15.3.1.2 Market Forecast (2026-2036)
15.3.2 Epilepsy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2020-2025)
15.3.2.2 Market Forecast by Therapies (2026-2036)
15.3.3 Epilepsy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Epilepsy - Market Size
15.4.1.1 Market Size (2020-2025)
15.4.1.2 Market Forecast (2026-2036)
15.4.2 Epilepsy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2020-2025)
15.4.2.2 Market Forecast by Therapies (2026-2036)
15.4.3 Epilepsy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Epilepsy - Market Size
15.5.1.1 Market Size (2020-2025)
15.5.1.2 Market Forecast (2026-2036)
15.5.2 Epilepsy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2020-2025)
15.5.2.2 Market Forecast by Therapies (2026-2036)
15.5.3 Epilepsy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Epilepsy - Market Size
15.6.1.1 Market Size (2020-2025)
15.6.1.2 Market Forecast (2026-2036)
15.6.2 Epilepsy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2020-2025)
15.6.2.2 Market Forecast by Therapies (2026-2036)
15.6.3 Epilepsy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Epilepsy - Market Size
15.7.1.1 Market Size (2020-2025)
15.7.1.2 Market Forecast (2026-2036)
15.7.2 Epilepsy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2020-2025)
15.7.2.2 Market Forecast by Therapies (2026-2036)
15.7.3 Epilepsy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Epilepsy - Market Size
15.8.1.1 Market Size (2020-2025)
15.8.1.2 Market Forecast (2026-2036)
15.8.2 Epilepsy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2020-2025)
15.8.2.2 Market Forecast by Therapies (2026-2036)
15.8.3 Epilepsy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Epilepsy - Market Size
15.9.1.1 Market Size (2020-2025)
15.9.1.2 Market Forecast (2026-2036)
15.9.2 Epilepsy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2020-2025)
15.9.2.2 Market Forecast by Therapies (2026-2036)
15.9.3 Epilepsy - Access and Reimbursement Overview
16 EPILEPSY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 EPILEPSY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 EPILEPSY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
